COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Study With a Topical Gel to Treat Common Warts in Adults

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00117923
Recruitment Status : Completed
First Posted : July 11, 2005
Last Update Posted : February 19, 2007
Information provided by:
Graceway Pharmaceuticals, LLC

Brief Summary:

The primary purpose of this study is to evaluate the effectiveness in adults of four different strengths of resiquimod gel applied to common wart(s) five times a week for four weeks.

A second purpose is to evaluate the safety of the drug.

Condition or disease Intervention/treatment Phase
Warts Drug: Resiquimod Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 88 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Single
Primary Purpose: Treatment
Official Title: A Three-Stage, Modified-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel Applied 5 Times Per Week for 4 Weeks for the Treatment of Common Warts in Adults
Study Start Date : August 2004

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Warts

Primary Outcome Measures :
  1. Clearance of treated wart(s)

Secondary Outcome Measures :
  1. Partial clearance of treated wart(s)
  2. Wart recurrence

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of common warts
  • Two forms of birth control

Exclusion Criteria:

  • Pregnant or breast feeding
  • Other types of warts, ie. plantar
  • Currently participating in another clinical study
  • Chronic viral hepatitis B or C

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00117923

Layout table for location information
United States, Oregon
Oregon Medical Research Center
Portland, Oregon, United States, 97223
Sponsors and Collaborators
Graceway Pharmaceuticals, LLC
Layout table for additonal information Identifier: NCT00117923    
Other Study ID Numbers: 1514-RESI
First Posted: July 11, 2005    Key Record Dates
Last Update Posted: February 19, 2007
Last Verified: November 2006
Keywords provided by Graceway Pharmaceuticals, LLC:
Common Warts
Additional relevant MeSH terms:
Layout table for MeSH terms
Papillomavirus Infections
DNA Virus Infections
Virus Diseases
Skin Diseases, Viral
Tumor Virus Infections
Skin Diseases, Infectious
Skin Diseases